ArticleFrontiers in pharmacology2026
Intraperitoneal administertion: compatibility and stability of common antibiotics in amino acid-based peritoneal dialysate.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The preferred method of antibiotic administration for peritoneal dialysis-related peritonitis is intraperitoneal. However, there are few studies on the compatibility of antibiotics in amino acid-based peritoneal dialysate. Methods: Our study employed High Performance Liquid Chromatography (HPLC) and amino acid analyzer to evaluate the stability of different antibiotics in amino acid-based peritoneal dialysate. We also used the two-dose method to detect the antimicrobial potency of gentamicin. Results: Gentamicin, ciprofloxacin, heparin Sodium and fluconazole showed excellent stability under different conditions (14 days at 4 °C: ≤3.57%, 14 days at 25 °C: ≤3.77%). β-Lactam antibiotics including meropenem, ceftazidime, cefotaxime, and aztreonam showed significant degradation, especially at high temperature (37 °C)(14 days at 4 °C: ≤59.98%, 14 days at 25 °C: 19.06%-84.97%, except for aztreonam demonstrating degradation at 48 h at 37 °C (18.51%-41.88%). Among them, meropenem was the least stable (14 days at 4 °C: 59.98%, 14 days at 25 °C: 84.97%). Low concentration vancomycin is relatively stable, while medium and high concentration vancomycin has poor stability (14 days at 4 °C 500 mg/L: 45.8%, 1 g/L 27.7%). Most amino acids remained basically stable under different antibiotic environments. We counted the degradation rate of all amino acids under different conditions. The maximum degradation rate appeared on glycine, but it was only 8.21%. Finally, we also found that the antibacterial efficacy of gentamicin in acid-based peritoneal dialysate was enhanced. Conclusion: Most antibiotics are stable in amino acid-based peritoneal dialysate. However, β-lactams (especially meropenem, ceftazidime, and cefotaxime) and medium-to-high dose vancomycin showed significant degradation and require prompt administration. The nutritional amino acid profile in dialysate remains largely unaffected. Gentamicin demonstrates enhanced antibacterial activity in the amino acid-based peritoneal dialysate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.